In a recent move by ArriVent BioPharma, Inc. (NASDAQ: AVBP), the company announced on April 20, 2024, that Kristine Peterson has been appointed to its Board of Directors, effective immediately. Peterson, with a notable career spanning over three decades in the pharmaceutical industry, will serve as a Class III Director until the 2027 annual meeting of stockholders.
Peterson's extensive experience includes her most recent role as CEO of Valeritas, Inc., from 2009 to 2016. Her tenure at Johnson & Johnson (NYSE:JNJ) as Company Group Chair of the biotechnology group from 2006 to 2009 saw her oversee commercial, research and development, and biologics manufacturing for oncology, immunology, and cell therapy. She also held executive positions at Biovail Corporation and spent 20 years in senior roles at Bristol-Myers Squibb Company (NYSE:BMY).
Alongside her executive career, Peterson has been active in governance roles, serving on the boards of Enanta Pharmaceuticals (NASDAQ:ENTA) and Immunocore Holdings, with past board roles at ImmunoGen (NASDAQ:IMGN), Inc., Amarin (NASDAQ:AMRN) Corporation plc, EyePoint Pharmaceuticals (NASDAQ:EYPT), and Paratek Pharmaceuticals (NASDAQ:PRTK).
Her contributions to the industry also include advisory positions with the Healthcare Businesswomen’s Association and the Biotechnology Industry Organization (BIO) Board.
ArriVent BioPharma's Board has determined that Peterson qualifies as an independent director under the Nasdaq Stock Market’s governance listing standards and the rules of the Securities Exchange Act of 1934. The company confirmed that there are no undisclosed arrangements or conflicts of interest concerning Peterson's appointment. As of now, the Board has not assigned Peterson to any specific committees.
Peterson holds a B.S. and an M.B.A. from the University of Illinois at Urbana-Champaign. Her appointment is expected to bring valuable insight and leadership to ArriVent BioPharma as it continues to navigate the pharmaceutical landscape.
The company has not disclosed any further details regarding Peterson's role or potential committee assignments. This information is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.